Journal of Allergy and Hypersensitivity Diseases最新文献

{"title":"Management of pollen and fruit allergy syndrome among French-speaking allergists: results from a survey and implications for clinical practice","authors":"Nhan Pham-Thi,&nbsp;Romain Montagne,&nbsp;Imene Ziane,&nbsp;Pascal Demoly","doi":"10.1016/j.jahd.2026.100071","DOIUrl":"10.1016/j.jahd.2026.100071","url":null,"abstract":"<div><h3>Background and objectives</h3><div>Pollen–food allergy syndrome is increasingly recognized as an emerging allergic health challenge, yet information on allergists' perceptions and management of pollen–food allergy syndrome in France is limited. This study aimed to characterize allergists’ perceptions of pollen–food allergy syndrome frequency and severity, as well as diagnosis and management strategies in France.</div></div><div><h3>Methods</h3><div>A 16-item online questionnaire was distributed to 1,329 physicians in the allergy group of the AdviceMedica platform in France (1 September–1 November 2025). Questions covered pollen–food allergy syndrome consultation frequency, perceived trends on incidence and symptom severity, suspected pollens, use of biological markers (PR-10, lipid transfer protein, gibberellin, profilin), therapeutic recommendations, and patterns of allergen immunotherapy use.</div></div><div><h3>Results</h3><div>A total of 126 physicians responded (9.5 %). Most reported prioritizing pollen–food allergy syndrome consultations (74.0 %), typically up to two per week. Nearly threequarters (73.8 %) perceived an increase in pollen–food allergy syndrome cases, mainly over the past 3 to 5 years. Pollen–food allergy symptoms were considered predominant in the overall clinical picture by 93.5 % of respondents; 47.9 % perceived increasing severity, although symptoms were usually mild and confined to the oropharyngeal cavity. Birch pollen was most frequently implicated, followed by grasses. Biomarker testing was requested in about one-quarter of cases (26.8 %); when performed, PR-10 was used by 100 % of respondents, with frequent use of lipid transfer protein (86.9 %), profilin (75.7 %), and gibberellin (44.9 %). Management strategies varied, including avoidance or nonavoidance of culprit foods and induction of food tolerance. Pollen–food allergy syndrome influenced AIT prescription choices for 49.6 % of allergists; however, 70.5 % never increased treatment doses, 23.8 % considered doing so in certain cases, and, if symptoms appeared during treatment, it was generally continued without dose escalation.</div></div><div><h3>Conclusions</h3><div>The respondents perceived pollen–food allergy syndrome as increasingly common and, in many cases, more severe, yet biomarker-based diagnosis is still used in only a minority of cases. pollen–food allergy syndrome may influence allergen immunotherapy selection, but dose adjustment is rarely performed once it has been initiated in this context. These findings highlight the need for clearer care pathways and prospective studies to define the role of allergen immunotherapy for pollen–food allergy syndrome.</div></div>","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"11 ","pages":"Article 100071"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148666748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug hypersensitivity in pregnancy: clinical spectrum and implications for obstetric care","authors":"Cintia Bassani,&nbsp;Lara Flavia Gobbi Cazarotto,&nbsp;Diane Gabrieli Tonin,&nbsp;Gabriel Leite Pertile,&nbsp;Betina Borghetti Secchi,&nbsp;Luciana Kase Tanno","doi":"10.1016/j.jahd.2026.100076","DOIUrl":"10.1016/j.jahd.2026.100076","url":null,"abstract":"<div><h3>Background</h3><div>Drug hypersensitivity reactions during pregnancy range from mild cutaneous manifestations to severe systemic events such as anaphylaxis. In addition to reactions occurring during gestation, pre-existing drug allergy labels may substantially influence therapeutic decisions and obstetric care.</div></div><div><h3>Objective</h3><div>To review the spectrum of drug hypersensitivity reactions during pregnancy, including pre-existing suspected drug allergies and reactions occurring during gestation, with emphasis on clinical manifestations, obstetric implications, and management strategies.</div></div><div><h3>Methods</h3><div>A systematic search of PubMed, Embase, and the Cochrane Library was conducted in November 2025 using terms related to pregnancy and drug hypersensitivity. Studies evaluating hypersensitivity reactions, drug allergy labels, or allergy assessment during pregnancy were considered eligible. Nine studies met the inclusion criteria, yielding ten independent datasets for qualitative synthesis.</div></div><div><h3>Results</h3><div>Eight datasets evaluated β-lactam antibiotics and two evaluated low-molecular-weight heparins. The prevalence of self-reported penicillin allergy ranged from 6 % to 8 %, whereas confirmed allergy was consistently below 10 % following formal evaluation. Severe reactions, including anaphylaxis, were uncommon. Inaccurate allergy labeling was associated with increased use of alternative antibiotics and potential adverse obstetric implications. In contrast, low-molecular-weight heparins were predominantly associated with delayed type IV cutaneous hypersensitivity reactions, which were generally managed by therapeutic substitution.</div></div><div><h3>Conclusions</h3><div>Drug hypersensitivity during pregnancy encompasses distinct clinical patterns according to the drug class involved. While β-lactam-associated reactions are primarily characterized by inaccurate allergy labeling and its therapeutic consequences, heparin-associated reactions are more commonly related to delayed cutaneous hypersensitivity. Structured risk assessment and appropriate diagnostic evaluation may optimize maternal and fetal outcomes.</div></div>","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"11 ","pages":"Article 100076"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149050864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug hypersensitivity in pregnancy: clinical spectrum and implications for obstetric care","authors":"Cintia Bassani,&nbsp;Lara Flavia Gobbi Cazarotto,&nbsp;Diane Gabrieli Tonin,&nbsp;Gabriel Leite Pertile,&nbsp;Betina Borghetti Secchi,&nbsp;Luciana Kase Tanno","doi":"10.1016/j.jahd.2026.100076","DOIUrl":"10.1016/j.jahd.2026.100076","url":null,"abstract":"<div><h3>Background</h3><div>Drug hypersensitivity reactions during pregnancy range from mild cutaneous manifestations to severe systemic events such as anaphylaxis. In addition to reactions occurring during gestation, pre-existing drug allergy labels may substantially influence therapeutic decisions and obstetric care.</div></div><div><h3>Objective</h3><div>To review the spectrum of drug hypersensitivity reactions during pregnancy, including pre-existing suspected drug allergies and reactions occurring during gestation, with emphasis on clinical manifestations, obstetric implications, and management strategies.</div></div><div><h3>Methods</h3><div>A systematic search of PubMed, Embase, and the Cochrane Library was conducted in November 2025 using terms related to pregnancy and drug hypersensitivity. Studies evaluating hypersensitivity reactions, drug allergy labels, or allergy assessment during pregnancy were considered eligible. Nine studies met the inclusion criteria, yielding ten independent datasets for qualitative synthesis.</div></div><div><h3>Results</h3><div>Eight datasets evaluated β-lactam antibiotics and two evaluated low-molecular-weight heparins. The prevalence of self-reported penicillin allergy ranged from 6 % to 8 %, whereas confirmed allergy was consistently below 10 % following formal evaluation. Severe reactions, including anaphylaxis, were uncommon. Inaccurate allergy labeling was associated with increased use of alternative antibiotics and potential adverse obstetric implications. In contrast, low-molecular-weight heparins were predominantly associated with delayed type IV cutaneous hypersensitivity reactions, which were generally managed by therapeutic substitution.</div></div><div><h3>Conclusions</h3><div>Drug hypersensitivity during pregnancy encompasses distinct clinical patterns according to the drug class involved. While β-lactam-associated reactions are primarily characterized by inaccurate allergy labeling and its therapeutic consequences, heparin-associated reactions are more commonly related to delayed cutaneous hypersensitivity. Structured risk assessment and appropriate diagnostic evaluation may optimize maternal and fetal outcomes.</div></div>","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"11 ","pages":"Article 100076"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149051319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to: “Guidelines on the diagnosis and management of perioperative immediate Hypersensitivity reactions 2025” J Allergy Hypersensitivity Dis 2026;10:100068","authors":"Paul Michel Mertès,&nbsp;Anca Chiriac,&nbsp;Charles Tacquard,&nbsp;Alain Facon,&nbsp;Sébastien Franchina,&nbsp;Aurélie Gouel-Chéron,&nbsp;Caroline Klingebiel,&nbsp;Corinne Lejus-Bourdeau,&nbsp;Diane Le Quang,&nbsp;Nidhal Leray-Touati,&nbsp;Dan Longrois,&nbsp;Claire Mailhol,&nbsp;Jean-Marc Malinosvsky,&nbsp;Isabelle Migueres,&nbsp;Moise Michel,&nbsp;Martine Morisset,&nbsp;Catherine Neukirch,&nbsp;Diane Pelletier de Chambure,&nbsp;Christelle Pellerin,&nbsp;Mélanie Perquin,&nbsp;Pascal Demoly","doi":"10.1016/j.jahd.2026.100077","DOIUrl":"10.1016/j.jahd.2026.100077","url":null,"abstract":"","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"11 ","pages":"Article 100077"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149050865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to: “Guidelines on the diagnosis and management of perioperative immediate Hypersensitivity reactions 2025” J Allergy Hypersensitivity Dis 2026;10:100068","authors":"Paul Michel Mertès,&nbsp;Anca Chiriac,&nbsp;Charles Tacquard,&nbsp;Alain Facon,&nbsp;Sébastien Franchina,&nbsp;Aurélie Gouel-Chéron,&nbsp;Caroline Klingebiel,&nbsp;Corinne Lejus-Bourdeau,&nbsp;Diane Le Quang,&nbsp;Nidhal Leray-Touati,&nbsp;Dan Longrois,&nbsp;Claire Mailhol,&nbsp;Jean-Marc Malinosvsky,&nbsp;Isabelle Migueres,&nbsp;Moise Michel,&nbsp;Martine Morisset,&nbsp;Catherine Neukirch,&nbsp;Diane Pelletier de Chambure,&nbsp;Christelle Pellerin,&nbsp;Mélanie Perquin,&nbsp;Pascal Demoly","doi":"10.1016/j.jahd.2026.100077","DOIUrl":"10.1016/j.jahd.2026.100077","url":null,"abstract":"","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"11 ","pages":"Article 100077"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149050862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of pollen and fruit allergy syndrome among French-speaking allergists: results from a survey and implications for clinical practice","authors":"Nhan Pham-Thi,&nbsp;Romain Montagne,&nbsp;Imene Ziane,&nbsp;Pascal Demoly","doi":"10.1016/j.jahd.2026.100071","DOIUrl":"10.1016/j.jahd.2026.100071","url":null,"abstract":"<div><h3>Background and objectives</h3><div>Pollen–food allergy syndrome is increasingly recognized as an emerging allergic health challenge, yet information on allergists' perceptions and management of pollen–food allergy syndrome in France is limited. This study aimed to characterize allergists’ perceptions of pollen–food allergy syndrome frequency and severity, as well as diagnosis and management strategies in France.</div></div><div><h3>Methods</h3><div>A 16-item online questionnaire was distributed to 1,329 physicians in the allergy group of the AdviceMedica platform in France (1 September–1 November 2025). Questions covered pollen–food allergy syndrome consultation frequency, perceived trends on incidence and symptom severity, suspected pollens, use of biological markers (PR-10, lipid transfer protein, gibberellin, profilin), therapeutic recommendations, and patterns of allergen immunotherapy use.</div></div><div><h3>Results</h3><div>A total of 126 physicians responded (9.5 %). Most reported prioritizing pollen–food allergy syndrome consultations (74.0 %), typically up to two per week. Nearly threequarters (73.8 %) perceived an increase in pollen–food allergy syndrome cases, mainly over the past 3 to 5 years. Pollen–food allergy symptoms were considered predominant in the overall clinical picture by 93.5 % of respondents; 47.9 % perceived increasing severity, although symptoms were usually mild and confined to the oropharyngeal cavity. Birch pollen was most frequently implicated, followed by grasses. Biomarker testing was requested in about one-quarter of cases (26.8 %); when performed, PR-10 was used by 100 % of respondents, with frequent use of lipid transfer protein (86.9 %), profilin (75.7 %), and gibberellin (44.9 %). Management strategies varied, including avoidance or nonavoidance of culprit foods and induction of food tolerance. Pollen–food allergy syndrome influenced AIT prescription choices for 49.6 % of allergists; however, 70.5 % never increased treatment doses, 23.8 % considered doing so in certain cases, and, if symptoms appeared during treatment, it was generally continued without dose escalation.</div></div><div><h3>Conclusions</h3><div>The respondents perceived pollen–food allergy syndrome as increasingly common and, in many cases, more severe, yet biomarker-based diagnosis is still used in only a minority of cases. pollen–food allergy syndrome may influence allergen immunotherapy selection, but dose adjustment is rarely performed once it has been initiated in this context. These findings highlight the need for clearer care pathways and prospective studies to define the role of allergen immunotherapy for pollen–food allergy syndrome.</div></div>","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"11 ","pages":"Article 100071"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148666747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Severe Anaphylaxis in France nEtwork (SAFE) project: a new anaphylaxis registry","authors":"Guillaume Pouessel ,&nbsp;Flore Amat ,&nbsp;Luc Colas ,&nbsp;Pascal Demoly ,&nbsp;Sylvie Leroy ,&nbsp;Paul-Michel Mertes ,&nbsp;Catherine Neukirch ,&nbsp;Céline Palussière ,&nbsp;Dominique Sabouraud-Leclerc ,&nbsp;Charles Tacquard ,&nbsp;Luciana Kase Tanno ,&nbsp;Joana Vitte","doi":"10.1016/j.jahd.2026.100069","DOIUrl":"10.1016/j.jahd.2026.100069","url":null,"abstract":"<div><div>Health registries improve our knowledge, support optimising care organisation and quality, and support the implementation of personalised medicine. While many registries collect data in the field of allergy and immunology worldwide, only few registries are dedicated to anaphylaxis. Despite a growing scientific interest in anaphylaxis over the past decade, current knowledge on severe anaphylaxis is insufficient, with many unresolved questions regarding risk factors, impact of cofactors, specific aspects in childhood, details related to trigger and the most appropriate therapeutic strategies. There is a clear need for health registries dedicated to severe anaphylaxis to address these gaps. This article aims first to present the rationale for creating a new registry dedicated to severe anaphylaxis by defining and describing health registries and related challenges in the field of anaphylaxis worldwide and in France, identifying knowledge gaps in severe anaphylaxis, and second to present the objectives of the new French anaphylaxis registry, named Severe Anaphylaxis in France nEtwork (SAFE). In 2026, the French professional council for allergy, in partnership with key allergy stakeholders in France, notably the Société française d'allergologie (the French allergy society), will inaugurate the SAFE registry in order to provide inputs on severe anaphylaxis, integrating all involved caregivers, including emergency care, anaesthesia and intensive care, paediatrics, research structures and patient associations.</div></div>","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"10 ","pages":"Article 100069"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148189488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic monoclonal antibodies in allergy: current landscape and future directions","authors":"Yves Renaudineau,&nbsp;Wesley Brooks","doi":"10.1016/j.jahd.2026.100070","DOIUrl":"10.1016/j.jahd.2026.100070","url":null,"abstract":"<div><div>Monoclonal antibodies have significantly revolutionized the therapeutic options available to allergists over the past two decades, encompassing four principal categories: anti-type E immunoglobulin (IgE) monoclonal antibodies (e.g., omalizumab), anti-interleukin (IL) 5/IL-5R monoclonal antibodies (e.g., mepolizumab, benralizumab), anti-IL-4R monoclonal antibodies (e.g., dupilumab), and anti-alarmin monoclonal antibodies (e.g., tezepelumab). The selection of an appropriate monoclonal antibody is guided by several factors, including disease severity, associated allergic and/or eosinophilic comorbidities, glucocorticoid dependence, and the presence of a type 2 allergic pattern characterized by specific IgE, eosinophils, and in asthma higher levels of fractional exhaled nitric oxide. In accordance with the selected criteria utilized to define therapeutic response, super-responders vary across studies, diseases, and biologics to constitute approximately 25 to 50 % of patients. Conversely, in up to 40 % of cases, switching therapies may be warranted due to inadequate or ineffective treatment response, glucocorticoid dependence, adverse effects, non-compliance, or, rarely, the development of antidrug antibodies. Discontinuation of antiallergic monoclonal antibodies carries a risk of therapeutic failure. However, this risk can be mitigated in selected and well-controlled patients or through gradual tapering strategies such as extending injection intervals or reducing dosages. Omalizumab, an anti-IgE monoclonal antibody, can be administered either as monotherapy in cases of food allergy, not as a curative intervention but to reduce the risk of allergic reactions, or in combination with allergen immunotherapy to attenuate initial allergic reactions, to accelerate desensitization, and to facilitate the consumption of allergenic foods in cases involving tropho-allergens. Emerging research continues to explore new targets, provide improvements in monoclonal antibody characteristics, as well as the development of biosimilars and multispecific monoclonal antibodies.</div></div>","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"10 ","pages":"Article 100070"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148657100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guidelines on the diagnosis and management of perioperative immediate hypersensitivity reactions 2025","authors":"Paul Michel Mertès,&nbsp;Anca Chiriac,&nbsp;Charles Tacquard,&nbsp;Alain Facon,&nbsp;Sébastien Franchina,&nbsp;Aurélie Gouel-Chéron,&nbsp;Caroline Klingebiel,&nbsp;Corinne Lejus-Bourdeau,&nbsp;Diane Le Quang,&nbsp;Nidhal Leray-Touati,&nbsp;Dan Longrois,&nbsp;Claire Mailhol,&nbsp;Jean-Marc Malinosvsky,&nbsp;Isabelle Migueres,&nbsp;Moise Michel,&nbsp;Martine Morisset,&nbsp;Catherine Neukirch,&nbsp;Diane Pelletier de Chambure,&nbsp;Christelle Pellerin,&nbsp;Mélanie Perquin,&nbsp;Pascal Demoly","doi":"10.1016/j.jahd.2026.100068","DOIUrl":"10.1016/j.jahd.2026.100068","url":null,"abstract":"<div><h3>Objective</h3><div>The Société française d'anesthésie et de réanimation (Sfar, the French society of anaesthesia and intensive care) and the Société française d'allergologie (SFA, the French society of allergy) have collaborated to propose guidelines for the diagnosis and management of perioperative immediate hypersensitivity reactions.</div></div><div><h3>Design</h3><div>A group of 23 French experts from the Sfar and the SFA was assembled. Any potential conflicts of interest were officially declared at the outset of the recommendations development process, which was conducted independently of any industry funding. The authors used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to assess the level of evidence in the literature.</div></div><div><h3>Methods</h3><div>Four fields were defined: (1) Diagnostic assessment of perioperative immediate hypersensitivity reactions; (2) Risk factors for perioperative immediate hypersensitivity reactions; (3) Treatment in scheduled and emergency situations and; (4) Treatment of perioperative immediate hypersensitivity reactions. For each field, the aim of the recommendations was to answer questions formulated by the experts according to the Population, Intervention, Comparison, Outcome (PICO) model. Based on these questions, an extensive literature search covering the last 24 years was carried out using predefined keywords according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations. The level of evidence was analysed using the GRADE method. The recommendations were formulated using the GRADE method, then voted on by all the experts using the GRADE grid method.</div></div><div><h3>Results</h3><div>The experts' summary work and the application of the GRADE method resulted in 70 recommendations concerning 31 questions. After three rounds of voting and several amendments, strong agreement was reached on 70 recommendations. Of these recommendations, six had a high level of evidence (six GRADE 1), 16 had a low level of evidence (16 GRADE 2) and 48 were expert opinions. Finally, for one question, no recommendation could be made.</div></div><div><h3>Conclusion</h3><div>There was strong agreement among the experts to formulate recommendations aimed at providing a benchmark for the diagnosis and management of perioperative immediate hypersensitivity reactions.</div></div>","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"10 ","pages":"Article 100068"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148737829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Administration of liquid sublingual immunotherapy using the iPUMP: The real-life SPEED study","authors":"Julien Cottet ,&nbsp;Éric Fromentin ,&nbsp;Houmam El Jurdi ,&nbsp;Imene Ziane ,&nbsp;Luciana Tanno ,&nbsp;Romain Montagne","doi":"10.1016/j.jahd.2026.100064","DOIUrl":"10.1016/j.jahd.2026.100064","url":null,"abstract":"<div><h3>Background and objectives</h3><div>Prior studies show that a small proportion of patients reach the recommended 3 years of treatment in allergen immunotherapy. Recently, a connected device (iPUMP®) was developed to enhance patient engagement and optimize treatment management of sublingual immunotherapy. The SPEED study evaluated the impact of the iPUMP on treatment adherence and persistence and examined the long-term use of sublingual immunotherapy in real-life.</div></div><div><h3>Methods</h3><div>The observational SPEED study consisted of two parts: a retrospective analysis to evaluate persistence, which tracked the renewal of sublingual immunotherapy using 22,250 orders (representing 10,567 treatments) from the Stallergenes Greer database; and a prospective survey conducted from May 29 to November 29, 2024, recruiting 381 patients starting sublingual immunotherapy for cat or house dust mites allergy. Patients were grouped into an iPUMP cohort (<em>n</em> = 181) and a standard care cohort (<em>n</em> = 200). Questionnaire data were collected after 3 months of treatment. Descriptive statistics were used for analysis of both components of the study.</div></div><div><h3>Results</h3><div>Eighty-two percent of patients using the iPUMP® renewed their sublingual immunotherapy, compared to 67 % of those who did not. The use of the iPUMP® consistently increased daily intake (consumption volumes) across all age groups. The connected device notably facilitated independence in younger patients. In the iPUMP® group, parental assistance decreased from 50 % at initiation to 29 % after 3 months, while in the standard care group, parental assistance increased in the same period (from 24 % to 58 %). Most parents (50 %) felt perfectly reassured about sublingual immunotherapy delivery when using the iPUMP®, compared to 36 % without the device. At treatment initiation, over 70 % of users reported reassurance regarding proper dose delivery, timing, and pressure control. As a treatment support, eight out of ten users found the iPUMP® helpful. A majority of both younger (80 % of 5 to 12-year-olds) and older (79 % of those over 12) patients believed the iPUMP® was an aid and plan to use it.</div></div><div><h3>Conclusions</h3><div>The study suggests a substantial impact of the iPUMP® on treatment renewal rates and treatment adherence, especially in younger patients. Consequently, it could be an effective tool to improve adherence to sublingual immunotherapy by facilitating an autonomous approach and strengthening parents' confidence.</div></div>","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"10 ","pages":"Article 100064"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148001553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}